摘要
目的:观察依折麦布联合阿托伐他汀对急性冠状动脉综合征(ACS)患者血脂及心脏事件的影响,并对其安全性评价。方法:回顾性分析北京安贞医院2010年1月至2010年12月间,住院的ACS患者236例,其中应用依折麦布(10 mg/d)联合阿托伐他汀(10 mg/d)治疗的患者81例(A组),应用阿托伐他汀(20 mg/d)治疗的患者155例(B组),治疗8 w后,比较两组患者治疗前后hs-CRP、LDL-C、TC、TG及HDL-C的变化,心脏事件以及不良反应发生率。结果:两组患者基线资料、治疗期间腹胀等不良反应及病死率差异无统计学意义(P>0.05),治疗8w后,A组hs-CRP、LDL-C、TC值、再发心绞痛及再发心肌梗死比例显著低于B组,差异有统计学意义(P<0.05)。结论:对ACS患者联合应用阿托伐他汀与依折麦布显著降低hs-CRP、LDL-C、TC水平及心脏事件发生率,且不增加不良反应,安全有效。
Objective:To observe the effects of ezetimibe combining atorvastatin on levels of blood lipid and major adverse cardiac events in patients with acute coronary syndrome(ACS).And do safety evaluation.Methods: Retrospective analysis of clinical data of 236 hospitalized patients with ACS in Anzhen Hospital from January 2010 to December 2010,Of these cases,81 received ezetimibe 10mg/d and atorvastatin 10mg/d treatment(group A),155 only received atorvastatin 20 mg/d treatment(group B).After 8 w treatment,hs-CRP,Low density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(hdl-C),major adverse cardiac events and adverse reaction rate in these two groups were compared with before and after treatment and each other to observe the therapeutic effects.Results: The baseline information of the patients,adverse reactions rate such as abdominal distension etc.and mortality were similar between the two groups(P0.05).After 8 w treatment,compared with pro-treatment,in group A the levels of hs-CRP,LDL-C,TC and the incidence of refractory angina,reinfarction are much lower than those in group B with statistical significance(P0.05).Conclusion: In ACS patients ezetimibe combining atorvastatin therapy could obviously lower the levels of hs-CRP,LDL-C,TC,the incidence of major adverse cardiac events.And did not increase the incidence of adverse reactions.It was safe and effective.
出处
《心肺血管病杂志》
CAS
2013年第3期259-261,共3页
Journal of Cardiovascular and Pulmonary Diseases